Domestic manufacturing incentives for vaccines

Introduction

Domestic manufacturing incentives for vaccines refer to financial, fiscal, regulatory and institutional measures adopted by governments to encourage the production of vaccines within the country. These incentives aim to strengthen public health security, reduce dependence on imported vaccines, promote pharmaceutical innovation and create employment opportunities.

In India, domestic vaccine manufacturing has significant importance because the country is a major producer of vaccines for national immunisation programmes and international markets. Government support for vaccine manufacturers also became particularly important during the COVID-19 pandemic, when reliable domestic production was essential for maintaining vaccine availability.

Domestic manufacturing incentives must balance industrial development with affordability, product quality, intellectual property protection and public health requirements.

Legal and policy framework in India

1. Production Linked Incentive Scheme

The Government of India introduced Production Linked Incentive (PLI) schemes to encourage domestic pharmaceutical manufacturing. The PLI Scheme for Pharmaceuticals supports eligible manufacturers through incentives linked to incremental production and investment, subject to notified conditions.

The scheme can support the development of pharmaceutical manufacturing capabilities, including eligible vaccine-related products. However, not every vaccine manufacturer or product automatically qualifies.

2. National Biopharma Mission

The National Biopharma Mission, implemented through the Biotechnology Industry Research Assistance Council (BIRAC), supports the development of affordable biopharmaceutical products. It promotes research partnerships, technology development, manufacturing capabilities and innovation in vaccines, biosimilars and other biological products.

3. Drugs and Cosmetics Act, 1940

This Act establishes the regulatory framework for the manufacture, distribution and sale of vaccines. Domestic manufacturers must comply with applicable licensing, quality-control and safety requirements.

4. New Drugs and Clinical Trials Rules, 2019

These rules regulate clinical trials and new drug approvals, including applicable requirements for vaccines. They establish procedures for regulatory applications, clinical research, safety monitoring and permissions.

5. Foreign Direct Investment Policy

India permits up to 100% foreign direct investment under the automatic route in the pharmaceutical sector for greenfield projects, subject to applicable policy conditions. Foreign investment can support vaccine manufacturing infrastructure, technology transfer and research partnerships.

Major domestic manufacturing incentives

1. Financial assistance and production incentives

Government incentive programmes encourage manufacturers to establish production facilities, expand existing plants and invest in advanced technologies. Financial assistance can reduce initial investment burdens and improve manufacturing competitiveness.

2. Research and development support

Vaccine development requires substantial expenditure on research, clinical trials, laboratory infrastructure and regulatory compliance. Programmes supported by BIRAC encourage collaboration between universities, research institutions, startups and pharmaceutical companies.

3. Infrastructure development

Domestic vaccine production requires specialised facilities, cold-chain systems, quality-control laboratories and reliable supply chains. Government support for industrial infrastructure and biotechnology parks can strengthen manufacturing capacity.

4. Technology transfer and public-private partnerships

Collaboration between government research institutions and private manufacturers helps convert scientific discoveries into commercially viable vaccines. Technology transfer agreements can improve production capacity and reduce dependence on imported technologies.

5. Public procurement and immunisation programmes

Government procurement creates predictable demand for vaccines. The Universal Immunisation Programme provides an important institutional market for qualifying vaccine manufacturers. Transparent procurement arrangements can encourage investment while ensuring public access and quality standards.

Important case laws

1. Novartis AG v. Union of India (2013)

The Supreme Court examined the patentability of a new form of an existing pharmaceutical substance under Section 3(d) of the Patents Act, 1970. The judgment emphasised that pharmaceutical innovation must satisfy statutory patentability requirements, including the enhanced therapeutic efficacy standard where applicable.

Its relevance to vaccine manufacturing lies in the relationship between intellectual property protection, innovation and affordable access to medicines. Domestic manufacturers must respect valid patent rights while benefiting from lawful opportunities for research and production.

2. Bayer Corporation v. Union of India (2014)

The Bombay High Court considered issues concerning compulsory licensing under the Patents Act, 1970. The dispute involved the interpretation of compulsory licensing provisions and the public interest in access to patented medicines.

The judgment is relevant because compulsory licensing may become important where patented technologies are necessary for public health and statutory requirements are satisfied. It illustrates the balance between patent protection and domestic access to essential medical products.

3. A.P. Pollution Control Board v. Prof. M.V. Nayudu (1999)

The Supreme Court discussed the precautionary principle and the importance of scientific expertise in environmental decision-making. Vaccine manufacturing facilities must comply with environmental and safety requirements, particularly where their operations involve biological materials, chemical substances and industrial waste.

4. Samira Kohli v. Dr. Prabha Manchanda (2008)

The Supreme Court explained the importance of informed consent in medical treatment. Although the case did not concern vaccine manufacturing incentives, its principles are relevant to vaccine clinical trials, where participant consent and ethical research practices are essential.

Challenges and regulatory concerns

Domestic vaccine manufacturers face several challenges, including high research costs, lengthy development periods, complex regulatory approvals and shortages of specialised raw materials. Smaller biotechnology companies may also struggle to obtain funding and establish advanced manufacturing infrastructure.

Incentive programmes must therefore operate transparently and should include measurable eligibility criteria, performance requirements and accountability mechanisms. Government support should not compromise vaccine safety, efficacy or affordability.

Conclusion

Domestic manufacturing incentives are essential for strengthening India's vaccine industry and improving national health security. Financial incentives, research support, infrastructure development, technology transfer and public procurement can encourage domestic production and scientific innovation. Indian patent and public health laws provide an important framework for balancing commercial interests with public access. A transparent incentive system combined with strict quality standards can help India maintain a competitive and reliable domestic vaccine manufacturing sector.